Clinigen Group (LON:CLIN)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a research report issued on Wednesday. They presently have a GBX 1,350 ($18.31) price target on the stock. Peel Hunt’s price target suggests a potential upside of 27.48% from the company’s previous close.
A number of other research firms have also recently commented on CLIN. Berenberg Bank assumed coverage on Clinigen Group in a research note on Wednesday, November 1st. They set a “hold” rating and a GBX 1,200 ($16.27) target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a GBX 1,360 ($18.44) target price on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, N+1 Singer reiterated a “buy” rating and set a GBX 1,225 ($16.61) target price on shares of Clinigen Group in a research note on Wednesday, November 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Clinigen Group currently has an average rating of “Buy” and an average price target of GBX 1,222.17 ($16.57).
Clinigen Group (CLIN) traded up GBX 9 ($0.12) during midday trading on Wednesday, hitting GBX 1,059 ($14.36). The stock had a trading volume of 664,427 shares, compared to its average volume of 372,742. The company has a market cap of $1,300.00 and a PE ratio of 35,300.00. Clinigen Group has a 12 month low of GBX 751.50 ($10.19) and a 12 month high of GBX 1,187 ($16.10).
ILLEGAL ACTIVITY WARNING: “Peel Hunt Reiterates “Buy” Rating for Clinigen Group (CLIN)” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/peel-hunt-reiterates-buy-rating-for-clinigen-group-clin/1846970.html.
Clinigen Group Company Profile
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.